Soohyeon Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2234073/publications.pdf

Version: 2024-02-01

58 papers	1,469 citations	17 h-index	330143 37 g-index
61	61	61	3231
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis (DEP). Lab on A Chip, 2011, 11, 1118.	6.0	389
2	Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nature Communications, 2018, 9, 1725.	12.8	122
3	Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer, 2011, 71, 89-93.	2.0	83
4	Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02. Journal of Clinical Oncology, 2013, 31, 1732-1739.	1.6	78
5	Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Research and Treatment, 2011, 129, 809-817.	2.5	76
6	Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta $Oncol\tilde{A}^3$ gica, 2013, 52, 73-81.	1.8	72
7	Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1203-1211.	2.5	43
8	Immune gene expression profiling reveals heterogeneity in luminal breast tumors. Breast Cancer Research, 2019, 21, 147.	5 . 0	43
9	Trends in receiving chemotherapy for advanced cancer patients at the end of life. BMC Palliative Care, 2015, 14, 4.	1.8	42
10	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. Supportive Care in Cancer, 2013, 21, 1751-1759.	2.2	38
11	Effects of a Mindfulness-Based Stress Reduction Program on the Physical and Psychological Status and Quality of Life in Patients With Metastatic Breast Cancer. Holistic Nursing Practice, 2017, 31, 260-269.	0.7	33
12	Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemotherapy and Pharmacology, 2010, 66, 507-516.	2.3	31
13	Characteristics of Venous Thromboembolism in Pancreatic Adenocarcinoma in East Asian Ethnics. Medicine (United States), 2016, 95, e3472.	1.0	24
14	Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram. Neuro-Oncology, 2012, 14, 1105-1113.	1.2	22
15	Extraosseous osteosarcoma: Single institutional experience in Korea. Asia-Pacific Journal of Clinical Oncology, 2010, 6, 126-129.	1.1	20
16	Psychosocial Impact of Cancer Patients on Their Family Members. Cancer Research and Treatment, 2013, 45, 226-233.	3.0	19
17	Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR. Yonsei Medical Journal, 2017, 58, 19.	2.2	19
18	Genomic Landscape and Clinical Utility in Korean Advanced Pan-Cancer Patients from Prospective Clinical Sequencing: K-MASTER Program. Cancer Discovery, 2022, 12, 938-948.	9.4	19

#	Article	IF	Citations
19	Radiation recall dermatitis induced by trastuzumab. Breast Cancer, 2016, 23, 159-163.	2.9	18
20	Patterns of Skin and Soft Tissue Metastases from Breast Cancer according to Subtypes: Relationship between EGFR Overexpression and Skin Manifestations. Oncology, 2011, 81, 55-62.	1.9	17
21	Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). Breast Cancer Research and Treatment, 2015, 152, 77-85.	2.5	17
22	Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib. Cancer Research and Treatment, 2016, 48, 403-408.	3.0	16
23	FOXP3 Expression Is Related to High Ki-67 Index and Poor Prognosis in Lymph Node-Positive Breast Cancer Patients. Oncology, 2013, 85, 128-136.	1.9	14
24	Hepatocellular carcinoma specific graded prognostic assessment can predict outcomes for patients with brain metastases from hepatocellular carcinoma. Journal of Neuro-Oncology, 2014, 120, 199-207.	2.9	14
25	Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Breast, 2022, 62, 52-60.	2.2	13
26	Anaplastic Lymphoma Kinase Gene Copy Number Gain in Inflammatory Breast Cancer (IBC): Prevalence, Clinicopathologic Features and Prognostic Implication. PLoS ONE, 2015, 10, e0120320.	2.5	12
27	Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project. Cancer Research and Treatment, 2021, 53, 123-130.	3.0	12
28	Overexpression of Reactive Oxygen Species Scavenger Enzymes Is Associated with a Good Prognosis in Triple-Negative Breast Cancer. Oncology, 2015, 88, 9-17.	1.9	11
29	Cranofacial osteosarcoma: Single institutional experience in <scp>K</scp> orea. Asia-Pacific Journal of Clinical Oncology, 2016, 12, e149-53.	1.1	11
30	Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. Investigational New Drugs, 2012, 30, 1150-1157.	2.6	10
31	Clinical Implication of Liquid Biopsy in Colorectal Cancer Patients Treated with Metastasectomy. Cancers, 2021, 13, 2231.	3.7	10
32	Treatment of recurrent hepatocellular carcinoma after liver transplantation. Asia-Pacific Journal of Clinical Oncology, 2011, 7, 258-269.	1.1	9
33	Ground-Glass Opacity in Lung Metastasis from Breast Cancer: A Case Report. Tuberculosis and Respiratory Diseases, 2013, 74, 32.	1.8	9
34	Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase II Trial (KCSG-BR 15-10). Cancers, 2020, 12, 3265.	3.7	9
35	Innovative countermeasures can maintain cancer care continuity during the coronavirus disease-2019 pandemic in Korea. European Journal of Cancer, 2020, 136, 69-75.	2.8	9
36	Case Series of Different Onset of Skin Metastasis According to the Breast Cancer Subtypes. Cancer Research and Treatment, 2014, 46, 194-199.	3.0	9

#	Article	IF	Citations
37	Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study. Cancer Research and Treatment, 2016, 48, 1373-1381.	3.0	9
38	Matrix Metalloproteinase-1 Expression Can Be Upregulated through Mitogen-Activated Protein Kinase Pathway under the Influence of Human Epidermal Growth Factor Receptor 2 Synergized with Estrogen Receptor. Molecular Cancer Research, 2010, 8, 1037-1047.	3.4	7
39	Salvage Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin (TIP) in Relapsed or Cisplatin-Refractory Germ Cell Tumors. Onkologie, 2011, 34, 416-420.	0.8	7
40	Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma. Investigational New Drugs, 2012, 30, 1768-1772.	2.6	7
41	Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing. Frontiers in Pharmacology, 2020, 11, 608774.	3.5	7
42	S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. BMC Cancer, 2013, 13, 583.	2.6	6
43	Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13). Cytokine, 2021, 142, 155487.	3.2	6
44	Prolonged clinical benefit from the maintenance hormone therapy inÂpatients with metastatic breast cancer. Breast, 2013, 22, 1205-1209.	2.2	5
45	Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10. Gynecologic Oncology, 2015, 136, 212-217.	1.4	4
46	Incidence and Clinical Outcomes of Febrile Neutropenia in Adult Cancer Patients with Chemotherapy Using Korean Nationwide Health Insurance Database. Yonsei Medical Journal, 2021, 62, 479.	2.2	4
47	Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations. Cancer Research and Treatment, 2022, 54, 30-39.	3.0	3
48	Safety of eribulin in Korean patients with metastatic breast cancer Journal of Clinical Oncology, 2015, 33, e12031-e12031.	1.6	3
49	Tolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis. Yonsei Medical Journal, 2020, 61, 837.	2.2	3
50	Genetic Characteristics Associated With Drug Resistance in Lung Cancer and Colorectal Cancer Using Whole Exome Sequencing of Cell-Free DNA. Frontiers in Oncology, 2022, 12, 843561.	2.8	3
51	Prognostic factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer: a retrospective study. Supportive Care in Cancer, 2022, 30, 8129-8137.	2.2	2
52	Physicians' attitudes towards the media and peer-review selection of the †best cancer doctor': comparison of two different selection methods. BMJ Open, 2018, 8, e019067.	1.9	0
53	The prognostic implications of redox protein expression in stage I-III triple-negative breast cancer Journal of Clinical Oncology, 2013, 31, 1035-1035.	1.6	0
54	Phase II study of gemcitabine and vinorebline in patients with persistent or recurrent platinum-resistant ovarian or primary peritoneal cancer: A study of the Korean Cancer Study Group Journal of Clinical Oncology, 2014, 32, 5568-5568.	1.6	O

SOOHYEON LEE

#	Article	IF	CITATIONS
55	Hepatocellular carcinoma specific graded prognostic assessment to predict the outcome for patients with brain metastases from hepatocellular carcinoma Journal of Clinical Oncology, 2014, 32, e15094-e15094.	1.6	0
56	RNA sequencing analysis and T-cell receptor repertoire in triple-negative breast cancer (TNBC) Journal of Clinical Oncology, 2020, 38, 1075-1075.	1.6	0
57	Predictive factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer Journal of Clinical Oncology, 2022, 40, 85-85.	1.6	0
58	Blood transfusion has an adverse impact on the prognosis of patients receiving chemotherapy for advanced colorectal cancer: experience from a single institution with a patient blood management program. Supportive Care in Cancer, 2022, 30, 5289-5297.	2.2	0